-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown virus has ravaged the world for more than a year, and my country's medium and high-risk areas have long been cleared, but foreign countries are still one after another, especially the United States is still adding tens of thousands each day.
Scientists even predict that the new crown virus will coexist with humans for a long time, but there is no effective way to cure the new crown pneumonia.
Mesenchymal stromal cells (MSC) are expected to be effective in the treatment of new coronary pneumonia, especially for critically ill patients.
Bone marrow mesenchymal stem cells derived from menstrual blood have received widespread attention due to their superior proliferation ability and lack of ethical issues.
From January to April 2020, the First Affiliated Hospital of Zhejiang University and the Affiliated People's Hospital of Wuhan University jointly launched a multi-center, open-label, non-randomized, parallel-controlled exploratory trial.
Recruited 44 patients, of which 26 patients received allogeneic menstrual blood-derived MSC treatment and simultaneously received drug therapy (experimental group), and 18 patients received only concurrent drug therapy (control group).
The experimental group was infused with 9×107 MSCs, divided into 3 times, once every other day.
Within 1 month after MSC infusion, the primary and secondary endpoints related to safety and effectiveness were evaluated at different time points.
The mortality of the experimental group was significantly lower than that of the control group (7.
69% vs 33.
33%; P=0.
048).
The dyspnea of the patients in the experimental group was significantly improved after each MSC infusion (day 1, 3, and 5).
In addition, the SpO2 of the experimental group was significantly improved with the infusion of MSC, and the results of chest imaging examination were significantly improved in the first month after the infusion of MSC (P<0.
05).
There was no difference in the incidence of most adverse reactions between the two groups.
In summary, MSC-based therapy may become a promising alternative method for the treatment of severe and critically ill coronary pneumonia.
Original source: Xu Xiaowei, Jiang Wanli, Chen Lijun et al.
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
Clin Transl Med, 2021, 11: e297.
For more information, please click to read the original text to download the Metz Medical APP~
Scientists even predict that the new crown virus will coexist with humans for a long time, but there is no effective way to cure the new crown pneumonia.
Mesenchymal stromal cells (MSC) are expected to be effective in the treatment of new coronary pneumonia, especially for critically ill patients.
Bone marrow mesenchymal stem cells derived from menstrual blood have received widespread attention due to their superior proliferation ability and lack of ethical issues.
From January to April 2020, the First Affiliated Hospital of Zhejiang University and the Affiliated People's Hospital of Wuhan University jointly launched a multi-center, open-label, non-randomized, parallel-controlled exploratory trial.
Recruited 44 patients, of which 26 patients received allogeneic menstrual blood-derived MSC treatment and simultaneously received drug therapy (experimental group), and 18 patients received only concurrent drug therapy (control group).
The experimental group was infused with 9×107 MSCs, divided into 3 times, once every other day.
Within 1 month after MSC infusion, the primary and secondary endpoints related to safety and effectiveness were evaluated at different time points.
The mortality of the experimental group was significantly lower than that of the control group (7.
69% vs 33.
33%; P=0.
048).
The dyspnea of the patients in the experimental group was significantly improved after each MSC infusion (day 1, 3, and 5).
In addition, the SpO2 of the experimental group was significantly improved with the infusion of MSC, and the results of chest imaging examination were significantly improved in the first month after the infusion of MSC (P<0.
05).
There was no difference in the incidence of most adverse reactions between the two groups.
In summary, MSC-based therapy may become a promising alternative method for the treatment of severe and critically ill coronary pneumonia.
Original source: Xu Xiaowei, Jiang Wanli, Chen Lijun et al.
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
Clin Transl Med, 2021, 11: e297.
For more information, please click to read the original text to download the Metz Medical APP~
